Recent Onset Type News Today

A new report builds on previous research that could help scientists better understand type 1 diabetes (T1D) risk.

MINNEAPOLIS, April 06, 2023 -- Panbela Therapeutics, Inc. , a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today... | April 6, 2023

Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today...

Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update News provided by Share this article Share this article RED BANK, N.J., May 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021. "The first quarter of 2021 marked another quarter of strong execution a...

DGAP-News: Imcys ... DGAP-News: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes vom 03.02.2021, 14:00 Uhr Bild: pixabay.com DGAP-News: Imcyse SA / Key word(s): Study Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes 03.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type...